{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-072397","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.579034+00:00","generated_at":"2026-05-23T23:00:18.393326+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aptose receives Nasdaq delisting notice for equity non-compliance; shares to be delisted Apr 2","bullets":["Nasdaq determined to delist Aptose effective April 2, 2025 for failure to meet minimum stockholder equity requirement under Rule 5550(b)(1).","Company received the delisting notice on March 31, 2025; will review options including appeal.","Aptose intends to continue executing business plan and seek listing on a U.S. national securities exchange.","Common shares remain listed on the Toronto Stock Exchange (TSX) under symbol 'APS'."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-072397","json":"https://secwatch.observer/filing/0001193125-25-072397.json","markdown":"https://secwatch.observer/filing/0001193125-25-072397.md","text":"https://secwatch.observer/filing/0001193125-25-072397.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000119312525072397/0001193125-25-072397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000119312525072397/d945844d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T23:00:18.393326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"458c628693bf8e59e3a3fe961fedba9a1af5e7eb","claim":"Aptose Biosciences Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"March 31, 2025, Aptose Biosciences Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not regained compliance with Nasdaq’s minimum stockholder equity requirement in Listing Rule 5550(b)(1), Nasdaq determined to delist the Company’s securities from The Nasdaq Stock Market, effective on April 2, 2025. The Company and board of directors will review all available options, including an appeal to the determination, but will continue to execute its business plan and will seek to list on a U.S. national securities exchange at the ap","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312525072397/0001193125-25-072397-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}